Product Details

Description

• Second-generation selective Janus kinase (JAK) inhibitor targeting the JAKl enzyme
• Approved by US Food and Drug Administration (FDA), the European Medical Agency (EMA) and National Institute for Health and Care Excellence (NICE)Inhibits progression of structural damage in patients with RA
• Effective in reducing signs and symptoms of disease and improving health-related quality of life (HR-QOL)
• Associated with rapid clinical response (54.2% on day 14) in ulcerative colitis